105 related articles for article (PubMed ID: 19001608)
21. The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination.
Monk BJ; Herzog TJ
Am J Obstet Gynecol; 2007 Oct; 197(4):337-9. PubMed ID: 17904955
[No Abstract] [Full Text] [Related]
22. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
[TBL] [Abstract][Full Text] [Related]
23. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
24. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention.
Castellsagué X; Klaustermeier J; Carrilho C; Albero G; Sacarlal J; Quint W; Kleter B; Lloveras B; Ismail MR; de Sanjosé S; Bosch FX; Alonso P; Menéndez C
Int J Cancer; 2008 Apr; 122(8):1901-4. PubMed ID: 18076064
[TBL] [Abstract][Full Text] [Related]
25. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
26. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
Setiawan D; Luttjeboer J; Westra TA; Wilschut JC; Suwantika AA; Daemen T; Atthobari J; Wilffert B; Postma MJ
Expert Rev Vaccines; 2015 Apr; 14(4):589-604. PubMed ID: 25482311
[TBL] [Abstract][Full Text] [Related]
27. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines.
Almonte M; Sasieni P; Cuzick J
Best Pract Res Clin Obstet Gynaecol; 2011 Oct; 25(5):617-29. PubMed ID: 21683657
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus: science and technologies for the elimination of cervical cancer.
Bosch FX
Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
[TBL] [Abstract][Full Text] [Related]
30. A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention.
Nowakowski A; Arbyn M; Turkot MH; Wieszczy P; Miłosz K; Kamiński MF; Didkowska J; Bidziński M; Olszewski W; Wielgoś M; Krzakowski M; Kuchar E; Walewski J
Eur J Cancer Prev; 2020 Mar; 29(2):157-164. PubMed ID: 31517672
[TBL] [Abstract][Full Text] [Related]
31. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
[TBL] [Abstract][Full Text] [Related]
33. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
[TBL] [Abstract][Full Text] [Related]
34. [Cervical HPV infection; epidemiology and vaccination].
Yoshikawa H
Kansenshogaku Zasshi; 2008 Nov; 82(6):609-12. PubMed ID: 19086414
[No Abstract] [Full Text] [Related]
35. Screening for cervical cancer: controversy and contention or thoughtful analysis.
Frable WJ
Cancer; 2007 Jun; 111(3):143-4. PubMed ID: 17487849
[No Abstract] [Full Text] [Related]
36. HPV genotypes: implications for worldwide cervical cancer screening and vaccination.
Wheeler CM
Lancet Oncol; 2010 Nov; 11(11):1013-4. PubMed ID: 20952255
[No Abstract] [Full Text] [Related]
37. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
38. HPV Vaccines: today and in the Future.
Moscicki AB
J Adolesc Health; 2008 Oct; 43(4 Suppl):S26-40. PubMed ID: 18809143
[TBL] [Abstract][Full Text] [Related]
39. Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine.
Angelo MG; Taylor S; Struyf F; Tavares Da Silva F; Arellano F; David MP; Dubin G; Rosillon D; Baril L
Expert Rev Vaccines; 2014 Nov; 13(11):1297-306. PubMed ID: 25219284
[TBL] [Abstract][Full Text] [Related]
40. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
